

New License Exception Authorizes Exports of Previously Restricted Medical Devices and Related Items to Russia, Belarus, Occupied Ukraine

May 6, 2024

The US Department of Commerce's Bureau of Industry and Security (BIS) added a new [License Exception for Medical Devices](#) (License Exception MED), effective April 29, 2024, authorizing exports, reexports and transfers of certain medical devices and related parts, components, accessories, and attachments for use therein to Russia, Belarus, and the Crimea, Donetsk People's Republic, and Luhansk People's Republic regions of Ukraine (collectively, the subject countries). License Exception MED likely will be a welcome change for clinical research, pharmaceutical and other medical device exporters who remain active in the subject countries, and is anticipated to reduce licensing volume for BIS significantly.

In response to Russia's February 2022 invasion of Ukraine, BIS expanded license requirements for exports to the subject countries of items subject to the Export Administration Regulations (EAR). Notably, BIS's license requirements previously applied to a broad range of medical devices and related items classified for export control purposes as EAR99 – a classification that typically does not trigger a country-based license requirement for Russia or Belarus. License Exception MED effectively eliminates these licensing requirements, subject to certain conditions.

For purposes of License Exception MED, "medical devices" are defined with reference to section 201 of the Federal Food, Drug, and Cosmetic Act and include – without limitation – medical supplies, instruments and equipment. To reduce the risk of diversion to industrial or military end uses, only parts, components, accessories and attachments that are necessary for replacement or maintenance in or with EAR99 medical devices are authorized.

Importantly, License Exception MED does not authorize:

1. Exports of covered medical items to restricted parties, including Entity List parties or military end users.
2. Exports to a "production facility" with knowledge or reason to know that the device is intended to develop or produce items (for purposes of this restriction, the assembly in a hospital or other healthcare facility of a finished medical device produced entirely outside the subject countries for the sole purpose of using that medical device at the same hospital or healthcare facility does not constitute "production").

Further, parties relying on License Exception MED "must maintain a system of distribution" to ensure that covered items are not delivered to restricted parties or used in production. Compliance verifications may involve obtaining documentation and affirmations from consignees and conducting periodic onsite spot-checks. Parties must maintain records of verifications for a period of five years (in addition to the standard recordkeeping requirements of the EAR).

Although License Exception MED provides relief to medical device exporters, exports to and other dealings with the subject countries remain considerably restricted. Importantly, US persons are prohibited from "new investment" and providing various services – including management consulting, accounting, and trust and corporate formation services. Accordingly, all activities involving the subject countries should be closely evaluated to ensure compliance with applicable laws and regulations.

Cooley closely monitors enforcement-related and other regulatory developments. If you have any questions, please reach out to

your Cooley contact or one of the lawyers listed below.

Cooley associate Shelby Saunders also contributed to this alert.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our [legal notices](#).

Key Contacts

Annie Froehlich Washington, DC	afroehlich@cooley.com +1 202 776 2019
Kevin King Washington, DC	kking@cooley.com +1 202 842 7823
Rebecca Ross Washington, DC	rross@cooley.com +1 202 728 7150
Karen Tsai Washington, DC	ktsai@cooley.com +1 202 842 7857
Sarah Oliai Washington, DC	soliai@cooley.com +1 202 728 7149
Shelby Saunders New York	ssaunders@cooley.com +1 212 479 6978

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.